ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition to qPCR for monitoring BCR::ABL1, ABL1 kinase domain point mutation analysis provides important clinical information in predicting resistance and choosing appropriate tyrosine kinase inhibitor (TKI)/treatment strategies in chronic myeloid leukaemia (CML).